{"version":"1.0","type":"link","title":"Cost-effectiveness analysis of Enfortumab vedotin and pembrolizumab for advanced urothelial carcinoma.","author_name":"Cheng H 외","author_url":"https://prs-insight.online/author/Cheng%20H","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/167010","thumbnail_width":1200,"thumbnail_height":630}